文献速递其他结缔组织病

SIGLEC1是原发性干燥综合征疾病活动度的生物标志物并提示腺外表现

SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sjögren's syndrome.
PubMed 文献 · RMD Open · 2016-12-30

该研究纳入31例符合美国-欧洲标准的原发性干燥综合征(pSS)患者,用流式细胞术检测单核细胞SIGLEC1表达、Bioplex法检测血清IP-10。结果发现SIGLEC1在腺外表现患者中100%(16/16)上调、仅腺体受累者27%(4/15)上调,可显著区分两组(p=0.0001),且与ESSDAI相关(p=0.005,r=0.54);IP-10无此区分能力。

要点

  • SIGLEC1在腺外表现pSS患者中100%上调,仅腺体受累者仅27%上调。
  • SIGLEC1可显著区分腺体与腺外亚组(p=0.0001),腺外预测阳性预测值80%。
  • SIGLEC1表达与ESSDAI相关(p=0.005,r=0.54),IP-10无此相关。

核心结论

  • SIGLEC1表达升高可标识pSS系统受累和高疾病活动度患者,可能有助于亚组定义、风险分层和治疗选择。

研究设计与样本

  • 纳入31例符合美国-欧洲标准pSS患者,用流式细胞术检测单核细胞SIGLEC1表达,Bioplex 27-plex kit检测血清IP-10,ESSDAI评估疾病活动度,Spearman秩检验做相关分析、Mann-Whitney U检验比较腺体与腺外表现差异。

主要发现

  • 64.5%的pSS患者SIGLEC1表达上调、78.9%血清IP-10升高,提示干扰素系统激活。
  • 腺外表现患者SIGLEC1上调16/16(100%),仅腺体受累者4/15(27%),两组差异显著(p=0.0001,Mann-Whitney U),腺外疾病阳性预测值80%。
  • SIGLEC1表达与疾病活动度相关(p=0.005,r=0.54,Spearman秩检验)。
  • 血清IP-10在腺体与腺外疾病间无显著差异,且与ESSDAI不相关。

关键数值与推荐

  • pSS诊断采用美国-欧洲标准;疾病活动度采用ESSDAI评估。
  • SIGLEC1区分腺体与腺外亚组的Mann-Whitney U检验p=0.0001,腺外疾病阳性预测值80%。
  • SIGLEC1与ESSDAI相关分析p=0.005、r=0.54(Spearman秩检验)。

临床怎么用

  • 对pSS患者检测单核细胞SIGLEC1表达,可能辅助识别系统受累高风险者和高疾病活动度患者,用于风险分层与治疗决策参考。

局限性

  • 样本量仅31例,结论需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the interferon (IFN) biomarkers sialic acid binding Ig like lectin 1 (SIGLEC1, CD169) and IFN-γ-inducible protein-10 (IP-10) in patients with primary Sjögren's syndrome (pSS). METHODS: 31 patients fulfilling the American-European criteria for pSS were included. Disease activity was obtained by EULAR Sjögren's syndrome disease activity index (ESSDAI). SIGLEC1 expression on monocytes was analysed using flow cytometry. IP-10 concentrations were determined using Bioplex human Cytokine 27-plex kit. Spearman rank test (SRT) was used for correlation analysis and Mann-Whitney U (MWU) to test for differences between glandular and extraglandular manifestations. RESULTS: An activated IFN system was detected by an upregulation of SIGLEC1 expression in 64.5% and by elevated serum level of IP-10 in 78.9% of our patients with pSS. In a subsequent analysis SIGLEC1 expression was found to be upregulated more frequently in patients with extraglandular manifestations (16/16, 100%) compared to patients with exclusively glandular involvement (4/15, 27%). SIGLEC1 expression could significantly discriminate between these two disease subgroups (p=0.0001, MWU) with a positive predictive value (PPV) of 80% for extraglandular disease. Moreover, the expression correlated with disease activity (p=0.005, r=0.54, SRT). Serum IP-10 levels neither differed significantly between glandular and extraglandular disease nor correlated with ESSDAI. CONCLUSIONS: Our results indicate that increased SIGLEC1 expression characterises patients with systemic involvement and high disease activity. Therefore, SIGLEC1 determination might be of value for subset definition, risk stratification and differential therapeutic considerations in pSS.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Rose T, Szelinski F, Lisney A, et al. SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sjögren's syndrome. RMD Open. 2016. PMID: 28123773. doi:10.1136/rmdopen-2016-000292

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。